Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease to Assess the Efficacy in Reducing Urinary Protein and Maintaining Podocyte Density and Function

NCT05709444 is registered in ClinicalTrials.gov with Palatin Technologies, Inc as lead sponsor.

NCT NCT05709444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05709444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease to Assess the Efficacy in Reducing Urinary Protein and Maintaining Podocyte Density and Function
Lead sponsor
Palatin Technologies, Inc
Phase
Phase 2
Overall status
Completed
Start date
December 26, 2022
Completion date
April 26, 2024
Enrollment
16 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

kidney disease